PARIS--(BUSINESS WIRE)--Regulatory News:
STENTYS (Paris:STNT) (FR0010949404 - STNT), a medical technology company commercializing the Xposition S self-apposing coronary stent, informs its shareholders that the Annual General Meeting held on May 14, 2018 was unable to deliberate, as the required quorum was not reached.
Shareholders are therefore invited to attend another Combined General Meeting, on the second call, to be held on Monday June 4, 2018 at 4.00 pm at 21 place de la Madeleine, 75008 Paris, the agenda of which will be the same.
All of the documents regarding this Combined General Meeting are available to shareholders upon request to STENTYS, 18 rue d’Hauteville, 75010 Paris, and can also be found on the Company website: www.stentys.com, Investors / Assemblée Générale (Shareholders’ Meetings): http://www.stentys.com/assemblée-générale.
The vote of shareholders who submitted their vote via the post for the first general meeting remains valid and counted for the general meeting on the second call.
STENTYS develops and commercializes innovative solutions for the treatment of patients with complex artery disease. STENTYS’ Self-Apposing® drug-eluting stents (DES) are designed to adapt to vessels with ambiguous or fluctuating diameters in order to prevent the malapposition problems associated with conventional stents. The APPOSITION clinical trials for the treatment of acute myocardial infarction showed a very low mortality rate at one year and a faster arterial healing compared to conventional stents. The company’s product portfolio also includes MiStent SES® and Serpentis, two innovative coronary DES for routine interventions, and is marketed through STENTYS’ commercial network in Europe, the Middle East, Asia and Latin America.
Additional information is available at www.stentys.com
STENTYS is listed on Compartment C of Euronext Paris
ISIN: FR0010949404 – Ticker: STNT
This press release contains forward-looking statements about the Company that are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which it will operate in the future which may not be accurate. Such forward-looking statements involve known and unknown risks which may cause the Company’s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with the development and commercialization of the Company’s products, market acceptance of the Company’s products, its ability to manage growth, the competitive environment in relation to its business area and markets, its ability to enforce and protect its patents and proprietary rights, uncertainties related to the U.S. FDA approval process, slower than expected rates of patient recruitment for clinical trials, the outcome of clinical trials, and other factors, including those described in the Section 4 “Risk Factors” of the Company’s 2016 Registration Document (document de référence) filed with the French Autorité des Marchés Financiers (AMF) on November 29, 2017 under number D.17-1084.